Norinchukin Bank The Grows Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Norinchukin Bank The boosted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 9.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,594 shares of the company’s stock after buying an additional 460 shares during the quarter. Norinchukin Bank The’s holdings in IDEXX Laboratories were worth $2,313,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of IDXX. Tidal Investments LLC increased its holdings in shares of IDEXX Laboratories by 7.6% in the 3rd quarter. Tidal Investments LLC now owns 6,310 shares of the company’s stock valued at $3,188,000 after acquiring an additional 444 shares during the last quarter. Franklin Resources Inc. boosted its holdings in IDEXX Laboratories by 2.5% in the third quarter. Franklin Resources Inc. now owns 1,412,700 shares of the company’s stock valued at $675,259,000 after purchasing an additional 34,305 shares in the last quarter. American Trust purchased a new position in IDEXX Laboratories in the third quarter valued at approximately $757,000. Oddo BHF Asset Management Sas acquired a new stake in IDEXX Laboratories during the third quarter worth approximately $1,128,000. Finally, GAMMA Investing LLC lifted its position in shares of IDEXX Laboratories by 3.3% during the 4th quarter. GAMMA Investing LLC now owns 1,533 shares of the company’s stock worth $634,000 after buying an additional 49 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at IDEXX Laboratories

In related news, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. This represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. 0.98% of the stock is currently owned by insiders.

IDEXX Laboratories Trading Up 2.3 %

Shares of IDXX stock opened at $411.72 on Monday. The company has a market capitalization of $33.37 billion, a P/E ratio of 38.59, a price-to-earnings-growth ratio of 3.41 and a beta of 1.50. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The business’s 50 day moving average is $422.37 and its two-hundred day moving average is $430.47. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $548.88.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on IDXX shares. Bank of America lifted their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. Morgan Stanley cut their target price on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Stifel Nicolaus decreased their target price on IDEXX Laboratories from $450.00 to $420.00 and set a “hold” rating for the company in a research report on Monday, April 14th. Barclays lifted their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. Finally, Piper Sandler increased their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $523.75.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.